Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 7071 (116th)

Accelerating Access to Critical Therapies for ALS Act

referredUnited States· United States Congress· EN

Introduced

1 June 2020

Last action

1 June 2020 · Introduced

Status

Referred to the House Committee on Energy and Commerce.

Sponsors

Rep. Fortenberry, Jeff [R-NE-1], Rep. Quigley, Mike [D-IL-5], Rep. Higgins, Clay [R-LA-3], Rep. Schweikert, David [R-AZ-1], Rep. Rouda, Harley [D-CA-48], Rep. Crow, Jason [D-CO-6], Rep. Sewell, Terri A. [D-AL-7], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Calvert, Ken [R-CA-41], Rep. Hill, J. French [R-AR-2], Rep. Neguse, Joe [D-CO-2], Rep. Crawford, Eric A. "Rick" [R-AR-1], Rep. Harris, Andy [R-MD-1], Rep. Womack, Steve [R-AR-3], Paul Cook, Rep. Cole, Tom [R-OK-4], Rep. Brooks, Mo [R-AL-5], Rep. Fleischmann, Charles J. "Chuck" [R-TN-3], Rep. Sires, Albio [D-NJ-13], Rep. King, Steve [R-IA-4], Rep. Van Drew, Jefferson [R-NJ-2], Rep. Beatty, Joyce [D-OH-3], Rep. Davis, Rodney [R-IL-13], Rep. Golden, Jared F. [D-ME-2], Rep. Scanlon, Mary Gay [D-PA-5], Rep. Stivers, Steve [R-OH-15], Rep. Westerman, Bruce [R-AR-4], Rep. Stanton, Greg [D-AZ-4], Rep. Holding, George [R-NC-2], Rep. Timmons, William R. [R-SC-4], Rep. Moolenaar, John R. [R-MI-2], Rep. King, Peter T. [R-NY-2], Rep. Ruppersberger, C. A. Dutch [D-MD-2], Rep. Meeks, Gregory W. [D-NY-5], Rep. Turner, Michael R. [R-OH-10], Rep. McClintock, Tom [R-CA-5], Rep. O'Halleran, Tom [D-AZ-1], Denver Riggleman, Rep. DesJarlais, Scott [R-TN-4], Rep. Langevin, James R. [D-RI-2], Rep. Luria, Elaine G. [D-VA-2], Rep. Green, Al [D-TX-9], Rep. Soto, Darren [D-FL-9], Rep. Peterson, Collin C. [D-MN-7], Rep. Cisneros, Gilbert Ray [D-CA-31], Rep. Katko, John [R-NY-24], Rep. Tlaib, Rashida [D-MI-12], Rep. Payne, Donald M., Jr. [D-NJ-10]

Subjects

Healthcare

Source updated

3 January 2025

Healthcare

Summary

Accelerating Access to Critical Therapies for ALS Act This bill establishes a grant program, as well as a new center within the Food and Drug Administration (FDA), to facilitate access to investigational therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (i.e., ALS, also known as Lou Gehrig's disease, a progressive and fatal disease). Specifically, the Department of Health and Human Services (HHS) must award grants for the provision of investigational drugs for ALS and other rapidly progressing neurodegenerative diseases through an expanded access (i.e., compassionate use) program. HHS may award these grants to (1) a small business that is the sponsor of an investigational new drug application, or (2) a participating clinical trial site for such a sponsor. Additionally, HHS must establish within the FDA a Center of Excellence for Neurodegenerative Diseases. The center shall have duties and authorities similar to those of the FDA's Oncology Center of Excellence, which helps expedite the development of medical products and assists providers in requesting access to investigational drugs.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 1 June 2020

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 1 June 2020

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 1 June 2020

    Introduced

    Introduced in House

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 1 June 2020

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 1 June 2020

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 1 June 2020

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 200 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.